Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024GlobeNewsWire • 01/10/24
Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its OwnershipBusiness Wire • 12/04/23
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineGlobeNewsWire • 11/12/23
Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/01/23
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance OfficerGlobeNewsWire • 10/31/23
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023GlobeNewsWire • 10/26/23
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023GlobeNewsWire • 10/19/23
Amarin Corporation plc (AMRN) Cantor Fitzgerald Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/27/23
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and ItalyGlobeNewsWire • 08/09/23
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in IsraelGlobeNewsWire • 08/08/23
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)GlobeNewsWire • 08/07/23
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South KoreaGlobeNewsWire • 07/31/23
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) CongressGlobeNewsWire • 07/26/23
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in SpainGlobeNewsWire • 07/25/23
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick HoltGlobeNewsWire • 07/20/23